Skip to main content
SpringerLink
Log in

Diabetic Neuropathies

Endpoints in Clinical Research Studies

  • Chapter
Controversies in Treating Diabetes

Part of the book series: Contemporary Endocrinology ((COE))

Summary

Clinical trials of agents for the treatment of diabetic neuropathy have been confronted with a lack of agreement on appropriate endpoints and have generated controversy on why ample demonstration of efficacy of an agent in animal studies has not been readily translated into success in human clinical trials. There has been a failure to recognize that the relief of symptoms does not equate to change in the underlying biological disorder and great disagreement on indices, which can reliably measure changes in nerve function which translate into changes in the quality of life, activities of daily living, and health of the individual. Here, one will focus on the various measures that have been used for the evaluation of symptoms and those that quantify nerve function and compare and contrast the reasons for failure of different measures neurological deficits, prevention of degeneration of specific small fiber, large fiber and autonomic nerve deficits and those that have potential for reversal of these deficits.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

references

  1. Young, M.J., Boulton, A.J.M., MacLeod, A.F., Williams, D.R.R., and Sonksen, P.H. 1993. A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 36:1–5.

    Article  Google Scholar 

  2. Dyck, P.J. 1988. Detection, characterization and staging of polyneuropathy: assessed in diabetes. Muscle Nerve 11:21–32.

    Article  PubMed  CAS  Google Scholar 

  3. Vinik, A.I. and Mitchell, B. 1988. Clinical aspects of diabetic neuropathies. Diabetes Metab Rev 4:223–253.

    PubMed  CAS  Google Scholar 

  4. Ziegler, D., Hanefeld, M., Ruhnau, K.J., Meissner, H.P., Lobisch, M., Schutte, K., and Gries, F.A. 1995. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 38:1425–1433.

    Article  PubMed  CAS  Google Scholar 

  5. Feldman, E.L., Stevens, M.J., Thomas, P.K., Brown, M.B., Canal, N., and Greene, D.A. 1994. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 17:1281–1289.

    Article  PubMed  CAS  Google Scholar 

  6. Apfel, S.C., Asbury, A., Bril, V., Burns, T., Campbell, J., Chalk,C., Dyck, P., Dyck, P.J., Feldman E, Fields, H. et al.2001. Positive neuropathic sensory symptoms as endpoints indiabetic neuropathy trials. J Neurol Sci 189:3–5 (Abstract).

    Article  PubMed  CAS  Google Scholar 

  7. Dyck, P.J., Davies, J.L., Litchy, W.J., and O’Brien, P.C. 1997. Longitudinal assessment of diabetic polyneuropathy using acomposite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 49:229–239.

    PubMed  CAS  Google Scholar 

  8. Melzack, R. 1999. Pain–an overview. Acta Anaesthesiol Scand43:880–884.

    Article  PubMed  CAS  Google Scholar 

  9. Gracely, R.H. 1999. Pain measurement. Acta AnaesthesiolScand 43:897–908.

    Article  CAS  Google Scholar 

  10. Bastyr, E., Zhang, D., Bril, V., and The MBBQ Study Group. 2002.Neuropathy Total symptom Score-6 Questionnaire (NTSS-6) Is a valid instrument for assessing the positive symptoms of diabetic peripheral neuropathy (DPN). Diabetes 51:A199.

    Google Scholar 

  11. Vinik, A., Bril, V., Kempler, P., Litchy, W., Dyck, P., Tesfaye,S., Price, K., Bastyr, E., and for the MBBQ Study. 2005. Treatment of symptomatic diabetic peripheral neuropathy with protein kinase CB inhibitor ruboxistaurin mesylate during a 1-year randomized,placebo-controlled, double-blind clinical trial. Clin Therap27:1164–1180.

    Article  CAS  Google Scholar 

  12. Raskin, P., Donofrio, P., Rosenthal, N., Hewitt, D., Jordan, D.,Xiang, J., and Vinik, A. 2004. Topiramate vs placebo in painful diabetic neuropathy: Analgesic and metabolic effects. Neurology 63:865–873.

    PubMed  CAS  Google Scholar 

  13. Boulton, A.J., Vinik, A.I., Arezzo, J.C., Bril, V., Feldman, E.L.,Freeman, R., Malik, R.A., Maser, R.E., Sosenko, J.M., and Ziegler,D. 2005. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28:956–962.

    Article  PubMed  Google Scholar 

  14. Vinik, A.I., Suwanwalaikorn, S., Stansberry, K.B., Holland, M.T.,McNitt, P.M., and Colen, L.E.1995.Quantitative measurement of cutaneous perception in diabetic neuropathy. Muscle Nerve18:574–584.

    Article  PubMed  CAS  Google Scholar 

  15. Low, P.A., Caskey, P.E., Tuck, R.R., Fealey, R.D., and Dyck, P.J.1983. Quantitative sudomotor axon reflex test in normal and neuropathic subjects. Ann Neurol 14:573–580.

    Article  PubMed  CAS  Google Scholar 

  16. Benbow, S. J., Wallmahmed, M. E., and MacFarlane, I. A. 1998.Diabetic peripheral neuropathy and quality of life. Q J Med91:733–737.

    CAS  Google Scholar 

  17. Fryback, D.G. 2005. A US valuation of the EQ-5D. Med Care43:199–200.

    Article  PubMed  Google Scholar 

  18. Ware, J.A. and Coller, B.S. 1995. Platelet morphology,biochemistry and function. In Williams Hematology. Beutler,E., Lichtman, M.A., Coller, B.S., and Kipps, T.J., editors. McGraw-Hill, New York, 1161–1201.

    Google Scholar 

  19. Grootenhuis, P.A., Snoek, F.J., Heine, R.J., and Bouter, L.M.1994. Development of a type 2 diabetes symptom checklist: ameasure of symptom severity. Diabet Med 11:253–261.

    PubMed  CAS  Google Scholar 

  20. Vinik, E., Hayes, R., Oglesby, A., Bastyr, E., Barlow, P.,Ford-Molvik, S., and Vinik, A. 2005. The Development and validation of the Norfolk QOL-DN a new measure of patients’perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther 7(3):497–508.

    Article  PubMed  Google Scholar 

  21. Vileikyte, L.,Peyrot, M., Bundy, C., Rubin, R.R., Leventhal, H.,Mora, P., Shaw, J.E., Baker, P., and Boulton, A.J. 2003. The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. Diabetes Care 26:2549–2555.

    Article  PubMed  Google Scholar 

  22. Vinik, E.J., Hayes, C., Oglesby, A., and Vinik, A.I. 2004.Identification of factors in the nerve fiber specific quality of life (QOL-DN) inventory that reflect QOL and health status. Diabetes 53:A295.

    Google Scholar 

  23. Vinik, E., Stansberry, K., Doviak, M., Ruck, S., and Vinik, A.2003. Norfolk quality of life (QOL) tool: scoring and reproducibility in healthy people, diabetic controls and patients with neuropathy. Diabetes 52(Suppl 1):A198.

    Google Scholar 

  24. DCCT Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 329:977–986.

    Article  Google Scholar 

  25. Sima, A.A., Bril, V., Nathaniel, V., McEwen, T.A., Brown, M.B.,Lattimer, S.A., and Greene, D.A. 1988. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med 319:548–555.

    Article  PubMed  CAS  Google Scholar 

  26. Dyck, P.J. and O’Brien, P.C. 1989. Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy. Diabetes Care 12:649–652.

    Article  PubMed  CAS  Google Scholar 

  27. Arezzo, J.C. 1997. The use of electrophysiology for the assessment of diabetic neuropathy. Neurosci Res Comm 21, 13–22.

    Article  Google Scholar 

  28. Vinik, A.I., Bril, V., Litchy, W.J., Price, K.L., and Bastyr,E.J., III. 2005. Sural sensory action potential identifies diabetic peripheral neuropathy responders to therapy. Muscle Nerve 32:619–625.

    Article  PubMed  Google Scholar 

  29. Kohara, N., Kimura, J., Kaji, R., Goto, Y., Ishii, J., Takiguchi,M., and Nakai, M. 2000. F-wave latency serves as the most reproducible measure in nerve conduction studies of diabetic polyneuropathy: multicentre analysis in healthy subjects and patients with diabetic polyneuropathy. Diabetologia43:915–921.

    Article  PubMed  CAS  Google Scholar 

  30. Vinik, A., Mehrabyan A., Colen, L., and Boulton, A. 2004. Focal entrapment neuropathies in diabetes. Diabetes Care 27(7):1783–1788.

    Article  Google Scholar 

  31. Sharma K., Cross J., Farronay O., Ayyar D., Sheber R., and Bradley W. 2002. Demyelinating neuropathy in diabetes mellitus. Arch Neurol 59:758–765.

    Article  PubMed  Google Scholar 

  32. Consensus Statement. 1988. Report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology. Diabetes Care 11:592–597.

    Google Scholar 

  33. Arezzo, J.C. and Zotova,E. 2002. Electro physiologic measures of diabetic neuropathy: mechanism and meaning. Int Rev Neurobiol 50:229–255.

    PubMed  Google Scholar 

  34. Shy, M.E., Frohman, E.M., So, Y.T., Arezzo, J.C., Cornblath, D.C.,Giuliani, M.J., and the subcommittee of the American Academy of Neurology. 2003. Quantitative sensory testing. Neurology602:898–906.

    Google Scholar 

  35. Bril, V., Kojic, J., Ngo, M., and Clark, K. 1997. Comparison of a neurothesiometer and vibration in measuring vibration perception thresholds and relationship to nerve conduction studies. Diabetes Care 20:1360–1362.

    Article  PubMed  CAS  Google Scholar 

  36. Dyck, P.J., Bushek, W., Spring, E.M., Karnes, J.L., Litchy, W.J.,O’Brien, P.C., and Service, F.J. 1987. Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy. Diabetes Care 10:432–440.

    Article  PubMed  CAS  Google Scholar 

  37. Steiness, I. 1957. Vibratory perception in diabetics; a biothesiometric study. Acta Med Scand 158:327–335.

    Article  PubMed  CAS  Google Scholar 

  38. Steiness, I. 1957. Vibratory perception in normal subjects; a biothesiometric study. Acta Med Scand 158:315–325.

    Article  PubMed  CAS  Google Scholar 

  39. Malik, R.A., Newrick, P.G., Sharma, A.K., Jennings, A., Ah-See, A.K., and Mayhew, T.M. 1989. Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy. Diabetologia 32:92–102.

    Article  PubMed  CAS  Google Scholar 

  40. Giannini, C. and Dyck, P. 1995. Basement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity. Ann Neurol 37:498–504.

    Article  PubMed  CAS  Google Scholar 

  41. Resnick, H.E., Vinik, A.I., Schwartz, A.V., Leveille, S.G.,Brancati, F.L., Balfour, J., and Guralnik, J.M. 2000. Independent effects of peripheral nerve dysfunction on lower-extremity physical function in old age: the Women’s Health and Aging Study. Diabetes Care 23:1642–1647.

    Article  PubMed  CAS  Google Scholar 

  42. Resnick, H.E., Stansberry, K.B., Harris, T.B., Tirivedi, M.,Smith, K., Morgan, P., and Vinik, A.I. 2002. Diabetes, peripheral neuropathy, and old age disability. Muscle Nerve 25:43–50.

    Article  PubMed  Google Scholar 

  43. Young, M.J., Breddy, J.L., Veves, A., and Boulton, A.J. 1994. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care 17:557–560.

    Article  PubMed  CAS  Google Scholar 

  44. Coppini, D.V., Young, P.J., Weng, C., MacLeod, A.F., and Sonksen,P.H. 1998. Outcome on diabetic foot complications in relation to clinical examination and quantitative sensory testing: a case-control study. Diabet.Med 15:765–771.

    Article  PubMed  CAS  Google Scholar 

  45. Abbott, C.A., Vileikyte, L., Williamson, S., Carrington, A.L., and Boulton, A.J. 1998. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 21:1071–1075.

    Article  PubMed  CAS  Google Scholar 

  46. Consensus Statement. 1992. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Muscle Nerve 15:1143–1170.

    Article  Google Scholar 

  47. Apfel, S.C., Schwartz, S., Adornato, B., Freeman, R., Biton, V.,Rendell, M., Vinik, A., Giuliani, M., Stevens, J., Barbano, R.,et al. 2000. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy. JAMA 284: 2215–2221.

    Article  PubMed  CAS  Google Scholar 

  48. Vinik, A.I., Maser, R.E., Mitchell, B.D., and Freeman, R. 2003.Diabetic autonomic neuropathy. Diabetes Care26(5):1553–1579.

    Article  Google Scholar 

  49. Suarez, G.A., Opfer-Gehrking, T.L., Offord, K.P., Atkinson, E.J.O’Brien, P.C., and Low, P.A. 1999. The Autonomic Symptom Profile:a new instrument to assess autonomic symptoms. Neurology 52:523–528.

    PubMed  CAS  Google Scholar 

  50. Low, P.A., Benrud-Larson, L.M., Sletten, D.M., Opfer-Gehrking,T.L., Weigand, S.D., O’Brien, P.C., Suarez, G.A., and Dyck, P.J.2004. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care 27:2942–2947.

    Article  PubMed  Google Scholar 

  51. Vinik, E., Snoek, F., Hayes, R., Oglesby, A., Bastyr, E., and Vinik, A. Validation of the Norfolk QOL-DN, a new measure of patients’ perception of the effects of diabetes and diabetic neuropathy. Diabetic Med (submitted).

    Google Scholar 

  52. Reaven, G.M., Lithell, H., and Lindsberg, L. 1996. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med334:374–381.

    Article  PubMed  CAS  Google Scholar 

  53. DeFronzo, R.A. and Ferrannini, E. 1991. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 14:173–194.

    Article  PubMed  CAS  Google Scholar 

  54. Ferrannini, E., Harrner, S.M., Nitchell, B.D., and Stern, M.P.1991. Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 34:416–422.

    Article  PubMed  CAS  Google Scholar 

  55. Zeng, G. and Quon, M.J. 1996. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in endothelial cells. J Clin Invest 98:894–898.

    Article  PubMed  CAS  Google Scholar 

  56. Baron, A.D., Laakso, M., Brechtel, G., and Edelman, S.V. 1991.Mechanism of insulin resistance in insulin-dependent diabetes mellitus: a major role for reduced skeletal muscle blood flow. J Clin Endocrinol Metab 73:637–643.

    PubMed  CAS  Google Scholar 

  57. Baron, A.D. 1999. Vascular reactivity. Am J Cardiol84:25J–27J.

    Article  PubMed  CAS  Google Scholar 

  58. Jaap, A.J., Hammersley, M.S., Shore, A.C., and Tooke, J.E. 1994.Reduced microvascular hyperaemia in subjects at risk of developing Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 37:214–216.

    Article  PubMed  CAS  Google Scholar 

  59. Caballero, A.E., Arora, S., Saouaf, R., Lim, S.C., Smakowski, P.,Park, J.Y., King, G.L., LoGerfo, F.W., Horton, E.S., and Veves, A. 1999. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes48:1856–1862.

    Article  PubMed  CAS  Google Scholar 

  60. Stansberry, K.B., Hill, M.A., Shapiro, S.A., McNitt, P.M., Bhatt,B.A., and Vinik, A.I. 1997. Impairment of peripheral blood flow responses in diabetes resembles an enhanced aging effect. Diabetes Care 20:1711–1716.

    Article  PubMed  CAS  Google Scholar 

  61. Vinik, A. I., Erbas, T., and Park, T. S. 2001. Methods for evaluation of peripheral neurovascular dysfunction. Diabetes Technol Ther 3:29–50.

    Article  PubMed  CAS  Google Scholar 

  62. Vinik, A., Erbas, T., Park, T., Stansberry, K., Scanelli, J., and Pittenger, G. 2001. Dermal neurovascular dysfunction in type 2 diabetes. Diabetes Care 24:1468–1475.

    Article  PubMed  CAS  Google Scholar 

  63. Pittenger, G., Simmons, K., Anandacoomaraswamy, D., Rice, A.,Barlow, P., and Vinik, A. 2005. Topiramate improves intraepidermal nerve fiber morphology and quantitative neuropathy measures in diabetic neuropathy patients. J Peripher Nerv Sys 10(Suppl1): (Abstract).

    Google Scholar 

  64. Vinik, A., Pittenger, G., Anderson, A., Stansberry, K., McNear,E., and Barlow, P. 2003. Topiramate improves C-fiber neuropathy and features of the dysmetabolic syndrome in type 2 diabetes. Diabetes 52(Suppl 1):A130.

    Google Scholar 

  65. Polydefkis, M., Griffin, J.W., and McArthur, J. 2003. New insights into diabetic polyneuropathy. JAMA 290:1371–1376.

    Article  PubMed  CAS  Google Scholar 

  66. Polydefkis, M., Hauer, P., Griffin, J.W., and McArthur, J.C. 2001.Skin biopsy as a tool to assess distal small fiber innervation in diabetic neuropathy. Diabetes Technol Ther 3:23–28.

    Article  PubMed  CAS  Google Scholar 

  67. Pittenger, G.L., Ray, M., Burcus, N.I., McNulty, P., Basta, B.,and Vinik, A.I. 2004. Intraepidermal nerve fibers are indicators of small-fiber neuropathy in both diabetic and nondiabetic patients. Diabetes Care 27:1974–1979.

    Article  PubMed  Google Scholar 

  68. Pittenger, G., Mehrabyan, A., Simmons, K., Rice, A., Barlow, P.,and Vinik, A. 2005. Small fiber neuropathy is associated with the metabolic syndrome. Metab Syndr Relat Disord 3(2):113–121.

    Article  CAS  PubMed  Google Scholar 

  69. Simone, D. A., Nolano, M., Johnson, T., Wendelschafer-Crabb, G.,and Kennedy, W. R. 1998. Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function. J Neurosci 18(21):8947–8959.

    PubMed  CAS  Google Scholar 

  70. Nolano, M., Simone, D.A., Wendelschafer-Crabb, G., Johnson, T.,Hazen, E., and Kennedy, W.R. 1999. Topical capsaicin in humans:parallel loss of epidermal nerve fibers and pain sensation. Pain 81:135–145.

    Article  PubMed  CAS  Google Scholar 

  71. Polydefkis, M., Hauer, P., Sheth, S., Sirdofsky, M., Griffin, J.W., and McArthur, J.C. 2004. The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain 127:1606–1615.

    Article  PubMed  Google Scholar 

  72. Vinik, A., Hewitt, D., and Xiang, J. 2003. Topiramate in the treatment of painful diabetic neuropathy: results from a multicenter, randomized, double-blind, placebo-controlled trial (abstract). Neurology 60(Suppl 1):A154–A155.

    Google Scholar 

  73. Albers, J.W., Brown, M.B., Sima, A.A., and Greene, D.A. 1996.Nerve conduction measures in mild diabetic neuropathy in the Early Diabetes Intervention Trial: the effects of age, sex, type of diabetes, disease duration, and anthropometric factors. Tolrestat Study Group for the Early Diabetes Intervention Trial. Neurology 46:85–91.

    PubMed  CAS  Google Scholar 

  74. Sima, A.A. and Laudadio, C. 1996. Design of controlled clinical trials for diabetic polyneuropathy. Semin Neurol16:187–191.

    PubMed  CAS  Google Scholar 

  75. Sundkvist, G., Armstrong, F.M., Bradbury, J.E., Chaplin, C., Ellis, S.H., Owens, D.R., Rosen, I., and Sonksen, P. 1992. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial. J Diabetes Complications 6:123–130.

    Article  PubMed  CAS  Google Scholar 

  76. Arezzo, J.C. 1999. New developments in the diagnosis of diabetic neuropathy. Am J Med 107:9S–16S.

    Article  PubMed  CAS  Google Scholar 

  77. Abraham, R.M. and Abraham, R.R. 1987. Absence of the sensory action potential of the medial plantar nerve: a sensitive indicator of diabetic neuropathy. Diabet Med 4:469–474.

    Article  PubMed  CAS  Google Scholar 

  78. Behse, F. and Buchthal. 1978. Sensory action potentials and biopsy of the sural nerve in neuropathy. Brain 101:473–493.

    Google Scholar 

  79. Izzo, K.L., Sobel, E., Berney, S., and Demopoulos, J.T. 1985. Distal sensory nerves of the lower extremity in peripheral neuropathy: comparison of medial dorsal cutaneous and sural nerve abnormalities. Arch Phys Med Rehabil 66:7–10.

    PubMed  CAS  Google Scholar 

  80. Izzo, K.L., Sobel, E., and Demopoulos, J.T. 1986. Diabetic neuropathy: electrophysiologic abnormalities of distal lower extremity sensory nerves. Arch Phys Med Rehabil 67:7–11.

    PubMed  CAS  Google Scholar 

  81. Killian, J.M. and Foreman, P.J. 2001. Clinical utility of dorsal sural nerve conduction studies. Muscle Nerve 24:817–820.

    Article  PubMed  CAS  Google Scholar 

  82. Shin, J.B., Seong, Y.J., Lee, H.J., Kim, S.H., Suk, H., and Lee, Y.J. 2000. The usefulness of minimal F-wave latency and sural/radial amplitude ratio in diabetic polyneuropathy. Yonsei Med J 41:393–397.

    PubMed  CAS  Google Scholar 

  83. Ekberg, K., Brismar, T., Johansson, B.L., Jonsson, B., Lindstrom, P., and Wahren, J. 2003. Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes. Diabetes 52:536–541.

    Article  PubMed  CAS  Google Scholar 

  84. Greene, D.A., Arezzo, J.C., and Brown, M.B. 1999. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology53:580–591.

    PubMed  CAS  Google Scholar 

  85. Laudadio, C., Pfeifer, M., Sima, A., and Ponalrestat group. 1998. Progression rates of diabetic neuropathy endpoints in patients assigned to placebo in an 10 month Clinical Research Trial. J Diabetes Complications 3:121–127.

    Article  Google Scholar 

  86. Ziegler, D., Mayer, P., Rathmann, W., and Gries, F.A. 1991. One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Diabetes Res Clin Pract14:63–73.

    Article  PubMed  CAS  Google Scholar 

  87. Ziegler, D., Mayer, P., Muhlen, H., and Gries, F.A. 1991. The natural history of somatosensory and autonomic nerve dysfunction in relation to glycaemic control during the first 5 years after diagnosis of type 1 (insulin-dependent) diabetes mellitus. Diabetologia 34:822–829.

    Article  PubMed  CAS  Google Scholar 

  88. Vinik, A., Tesfaye, S., Zhang, D., and Bastyr, E. 2002.LY333531 treatment improves diabetic peripheral neuropathy (DPN) with symptoms. Diabetes 51(Suppl 2):A79.

    Google Scholar 

Download references

Authors
  1. Aaron I. Vinik MD, PHD, FCP, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Diabetes, and Bone Disease, Department of Medicine, Mount Sinai School of Medicine, New York, NY

    Derek LeRoith MD PhD

  2. Diabetes Research Institute Department of Medicine, Eastern Virginia Medical School The Leonard Strelitz Diabetes Institutes, Norfolk, VA

    Aaron I. Vinik MD PhD FCP FACP

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press

About this chapter

Cite this chapter

Vinik, A.I. (2008). Diabetic Neuropathies. In: LeRoith, D., Vinik, A.I. (eds) Controversies in Treating Diabetes. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-59745-572-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-572-5_8

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-708-2

  • Online ISBN: 978-1-59745-572-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation